Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Barbara Wyroba"'
Autor:
Denver D. Britto, Barbara Wyroba, Wenxuan Chen, Rhoswen A. Lockwood, Khanh B. Tran, Peter R. Shepherd, Christopher J. Hall, Kathryn E. Crosier, Philip S. Crosier, Jonathan W. Astin
Publikováno v:
Disease Models & Mechanisms, Vol 11, Iss 12 (2018)
Tumour angiogenesis has long been a focus of anti-cancer therapy; however, anti-angiogenic cancer treatment strategies have had limited clinical success. Tumour-associated myeloid cells are believed to play a role in the resistance of cancer towards
Externí odkaz:
https://doaj.org/article/3c094a499148435da8da2dd6b73c0cf5
Autor:
Renata Mężyk-Kopeć, Barbara Wyroba, Krystyna Stalińska, Tomasz Próchnicki, Karolina Wiatrowska, Witold W Kilarski, Melody A Swartz, Joanna Bereta
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0132661 (2015)
Tumor-associated lymphatic vessels actively participate in tumor progression and dissemination. ADAM17, a sheddase for numerous growth factors, cytokines, receptors, and cell adhesion molecules, is believed to promote tumor development, facilitating
Externí odkaz:
https://doaj.org/article/ca5c9b3bc81c43888bc051bdfae04a8d
Autor:
Sudipta Das, Maria Czarnek, Monika Bzowska, Renata Mężyk-Kopeć, Krystyna Stalińska, Barbara Wyroba, Jolanta Sroka, Jarosław Jucha, Dawid Deneka, Paulina Stokłosa, Justyna Ogonek, Melody A Swartz, Zbigniew Madeja, Joanna Bereta
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e50791 (2012)
ADAM17 (a disintegrin and metalloprotease 17) is a major sheddase for numerous growth factors, cytokines, receptors, and cell adhesion molecules and is often overexpressed in malignant cells. It is generally accepted that ADAM17 promotes tumor develo
Externí odkaz:
https://doaj.org/article/8656bee2c12d4a449e7fa9ea5ac56467
Autor:
Philip S. Crosier, Christopher J. Hall, Wenxuan Chen, Peter R. Shepherd, Jonathan W. Astin, Kathryn E. Crosier, Barbara Wyroba, Denver D. Britto, Khanh Bao Tran, Rhoswen A. Lockwood
Publikováno v:
Disease Models & Mechanisms
Disease Models & Mechanisms, Vol 11, Iss 12 (2018)
Disease Models & Mechanisms, Vol 11, Iss 12 (2018)
Tumour angiogenesis has long been a focus of anti-cancer therapy; however, anti-angiogenic cancer treatment strategies have had limited clinical success. Tumour-associated myeloid cells are believed to play a role in the resistance of cancer towards
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68dca674268d54851941c1574648fb08
https://ruj.uj.edu.pl/xmlui/handle/item/70786
https://ruj.uj.edu.pl/xmlui/handle/item/70786
Autor:
Tomasz Próchnicki, Melody A. Swartz, Barbara Wyroba, Joanna Bereta, Karolina Wiatrowska, Krystyna Stalińska, Renata Mężyk-Kopeć, Witold W. Kilarski
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 7, p e0132661 (2015)
PLoS ONE, Vol 10, Iss 7, p e0132661 (2015)
Tumor-associated lymphatic vessels actively participate in tumor progression and dissemination. ADAM17, a sheddase for numerous growth factors, cytokines, receptors, and cell adhesion molecules, is believed to promote tumor development, facilitating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf0e0d0e80d3579cdc3a7f74d59e7e8c
https://pubmed.ncbi.nlm.nih.gov/26176220
https://pubmed.ncbi.nlm.nih.gov/26176220
Autor:
Jarosław Jucha, Barbara Wyroba, Joanna Bereta, Justyna Ogonek, Melody A. Swartz, Zbigniew Madeja, Paulina Stokłosa, Maria Czarnek, Jolanta Sroka, Monika Bzowska, Dawid Deneka, Krystyna Stalińska, Sudipta Das, Renata Mężyk-Kopeć
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e50791 (2012)
PLoS ONE
PLoS ONE
ADAM17 (a disintegrin and metalloprotease 17) is a major sheddase for numerous growth factors, cytokines, receptors, and cell adhesion molecules and is often overexpressed in malignant cells. It is generally accepted that ADAM17 promotes tumor develo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1ef75eab45928e04a8ec42200dbb66e
http://europepmc.org/articles/PMC3519469?pdf=render
http://europepmc.org/articles/PMC3519469?pdf=render